Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for TYRA-300 in Pediatric Achondroplasia. The expected timing is based on the latest available company guidance and may change.
BEACH301 trial. 10/28/24- IND cleared. 8/21/25- First participant dosed. Initial results from safety sentinel cohort in H2 2026. 11/05/25:- BEACH301 Phase 2 study is enrolling the safety sentinel cohort and remains on track to report interim results from this cohort in H2 2026. 03/02/26:- BEACH301 sentinel cohort enrolling; two of four doses cleared safely; interim height data expected 2H 2026. 08/04/26:- BEACH301 data now expected end of Q1 2027; fifth dose level opened.
Verification
Confirm timing and program details against the company announcement or filing.